Santhera Pharmaceuticals Holding AG (0QN1.L) LSE
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Santhera Pharmaceuticals Holding AG
Address
Hohenrainstrasse 24
Pratteln, 4133
Switzerland
Phone
41 61 906 89 50
Website
Sector
Healthcare
Industry
Biotechnology
Employees
78
First IPO Date
March 06, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Dario Eklund | Chief Executive Officer | 1.23M | 1968 |
| Thomas Meier | Founder & Chairman | 200,000 | 1962 |
| Sarah Holmes-Klotz | Global Head of People & Culture | 0 | N/A |
| Oliver Kronenberg | Chief Legal Officer & Corporate Secretary | 0 | 1968 |
| Shabir Hasham | Chief Medical Officer | 0 | 1970 |
| Andreas Missy | Executive Vice President of Corporate Planning & Business Development | 0 | N/A |
| Catherine Ann Isted | Chief Financial Officer | 0 | 1975 |
| Oliver Strub | Head of Compliance | 0 | 1963 |
| Neville Kodkani | Head of Global Marketing & Partner Management | 0 | N/A |
| Marc Schrader | Chief Technology Officer | 0 | 1971 |
| Geert Jan van Daal | Chief Commercial Officer | 0 | 1960 |
Description
Santhera Pharmaceuticals Holding AG, established in 2004 and based in Pratteln, Switzerland, is a specialized pharmaceutical company. The firm and its subsidiaries are dedicated to developing and marketing medications for rare neuromuscular and pulmonary diseases with significant unmet medical needs, serving patients across the European Union and internationally. Santhera's lead drug in development is vamorolone, which is being advanced as a treatment for Duchenne muscular dystrophy (DMD). The company's clinical-stage pipeline also features lonodelestat (POL6014) for addressing cystic fibrosis and other neutrophilic pulmonary conditions, as well as omigapil, designed to treat congenital muscular dystrophies. Furthermore, Santhera has out-licensed the rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy in all regions except North America and France.
